Melvyn Little

Melvyn Little received his degree in chemistry and PhD in biochemistry from Bangor University, Wales and subsequently completed a Postdoc at the Max-Planck-Institute for Cell Biology in Wilhelmshaven, Germany. He has served as head of the Research Group "Recombinant Antibodies" at the German Cancer Research Center in Heidelberg and as an External Professor of Biochemistry at Heidelberg University. In addition, he was a Co-founder and Supervisory Board Member of the biotech firm Affitech in...See more

Melvyn Little received his degree in chemistry and PhD in biochemistry from Bangor University, Wales and subsequently completed a Postdoc at the Max-Planck-Institute for Cell Biology in Wilhelmshaven, Germany. He has served as head of the Research Group "Recombinant Antibodies" at the German Cancer Research Center in Heidelberg and as an External Professor of Biochemistry at Heidelberg University. In addition, he was a Co-founder and Supervisory Board Member of the biotech firm Affitech in Oslo, Norway, as well as Founder and Management Board Member of the biotech firm Affimed in Heidelberg. His primary research interest is in the development of dual binding antibodies for recruiting killer immune cells to destroy tumor cells. Currently he is in retirement and a biotechnology consultant. See less